N-substituted-1,2,4-triazolone compounds for treatment of cardiovascular disorders
CA 2083735 A1 · Owner: Searle (G. D.) & Co. · Inventors: Huang, Horng-Chih; Reitz, David B.; Manning, Robert E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A class of N-substituted-1,2,4-triazolone compounds is described for use in treatment of cardiovascular disorders. Compounds of particular interest are angiotensin II antagonists of formula (I) wherein R1 is selected from, 2-oxo-2-(tricyclo3.3.1.1.3.7dec-2-yl)ethyl 3-phenylpropyl, 2-oxo-2-phenylethyl, 2-hyroxy-2-phenylethyl 1,1-dimethylethyloxycarbonylmethyl, hexyl ethoxycarbonylmethyl, carboxymethyl, 1-naphthalenylmethyl 2-cyclohexylethyl, pentyl, ethoxycarbonylmethoxyethyl substituted with phenyl carboxymethoxyethyl , substituted with phenyl 3,5,5-trimethylhexyl, (2-phenylmethoxy)-1-(phenylmethyl)-E-ethenyl 1-benzoyl-2-phenylethyl, 1-oxobutyl, 2-(2,5-dimethyoxyphenyl)-2-oxoethyl …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 23, 1991. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 23, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 23, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.